Exelixis Inc

EXEL:NASDAQ
RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:01 PM EST
22.32UNCH (UNCH)
Volume
60,144
Close
22.32quote price arrow down-0.14 (-0.62%)
Volume
2,243,175
52 week range
13.67 - 27.80

...

Loading . . .

KEY STATS

  • Open22.20
  • Day High22.65
  • Day Low21.58
  • Prev Close22.46
  • 52 Week High27.80
  • 52 Week High Date05/12/20
  • 52 Week Low13.67
  • 52 Week Low Date03/17/20
  • Market Cap6,924.56M
  • Shares Out310.24M
  • 10 Day Average Volume3.01M
  • Dividend-
  • Dividend Yield-
  • Beta1.13
  • 1 Year % Change25.82

RATIOS/PROFITABILITY

  • EPS (TTM)0.48
  • P/E (TTM)46.64
  • Fwd P/E (NTM)72.94
  • EBITDA (MRQ)172.07M
  • ROE (MRQ)8.80%
  • Revenue (MRQ)957.80M
  • Gross Margin (MRQ)96.06%
  • Net Margin (MRQ)15.88%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date02/10/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Exelixis Inc News

There is no recent news for this security.

Latest EXEL News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ capsules are approved for progressive, metastatic medullary thyroid...
Stelios Papadopoulos Ph.D.
Chairman
Michael Morrissey Ph.D.
Chief Executive Officer
Christopher Senner CPA
Chief Financial Officer
Patrick Haley
Executive Vice President
Jeffrey Hessekiel J.D.
Executive Vice President
Address
1851 Harbor Bay Pkwy
Alameda, CA
94502-3016
United States